Separately, the FDA on Friday informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, that is approved to treat a different type of muscular dystrophy and was ...

Sarepta stock (SRPT) declined 5% in premarket trade, after falling 36% on Friday, when it disclosed a patient death due to liver failure.

Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...

Sarepta Therapeutics has rejected a call by the Food and Drug Administration to stop shipments of its muscular dystrophy drug.

US stocks rose on Monday, with fresh records for the Nasdaq Composite (^IXIC) and S&P 500 (^GSPC) in sight as Wall Street ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Verizon Communications helped lead the way and rose 4.8%. The telecom reported a stronger profit for the latest quarter than ...

Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...

While most investors chase yesterday's headlines, Tim Melvin spots tomorrow's winners. See the exact system that found NVIDIA ...

Investing.com - Verizon Communications has lifted the lower end of its full-year adjusted earnings per share forecast and core profit in the telecoms group’s second quarter topped estimates, sending ...